OpenEvidence stock $488.73 USD
Private-market facts for current and former OpenEvidence employees researching their stock.
Price per share sourced from public secondary-market data. Updated April 2026. Indicative only — not a live quote.
Overview
OpenEvidence provides an AI platform for physicians that synthesizes medical research and clinical evidence to support clinical decision-making.
Selling OpenEvidence shares
Why shareholders consider selling
Shareholders in OpenEvidence may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, OpenEvidence does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell OpenEvidence stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing OpenEvidence shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of OpenEvidence shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series A round, its reported $12B valuation and recent secondary-market pricing can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for OpenEvidence shareholders
Exploring equity in OpenEvidence often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
OpenEvidence most recently raised a Series A round . The company was valued at $12B. Total funding raised to date is approximately $75M.
Industry
Similar private companies
Latest OpenEvidence news
Frequently asked questions
- Is OpenEvidence still a private company?
- Yes, OpenEvidence is currently a private company.
- What is OpenEvidence's latest funding round?
- OpenEvidence's most recent known round is Series A.
- What is OpenEvidence's valuation?
- OpenEvidence's latest reported valuation is $12B.
- Who are the investors in OpenEvidence?
- Investor information is not currently available.
- Can I sell my OpenEvidence stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands OpenEvidence stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · OpenEvidence data compiled from funding disclosures, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.